Display options
Share it on

Drug Saf. 2018 Sep;41(9):849-857. doi: 10.1007/s40264-018-0666-y.

Comparison of Data on Serious Adverse Events and Mortality in ClinicalTrials.gov, Corresponding Journal Articles, and FDA Medical Reviews: Cross-Sectional Analysis.

Drug safety

Richeek Pradhan, Sonal Singh

Affiliations

  1. Department of Quantitative Health Sciences, University of Massachusetts Medical School, 55 Lake Ave North, Worcester, MA, 01655-0002, USA.
  2. Department of Family Medicine and Community Health, Meyers Primary Care Institute, University of Massachusetts Medical School, 55 Lake Ave North, Worcester, MA, 01655-0002, USA. [email protected].

PMID: 29644579 DOI: 10.1007/s40264-018-0666-y

Abstract

INTRODUCTION: Inconsistencies in data on serious adverse events (SAEs) and mortality in ClinicalTrials.gov and corresponding journal articles pose a challenge to research transparency.

OBJECTIVE: The objective of this study was to compare data on SAEs and mortality from clinical trials reported in ClinicalTrials.gov and corresponding journal articles with US Food and Drug Administration (FDA) medical reviews.

METHODS: We conducted a cross-sectional study of a randomly selected sample of new molecular entities approved during the study period 1 January 2013 to 31 December 2015. We extracted data on SAEs and mortality from 15 pivotal trials from ClinicalTrials.gov and corresponding journal articles (the two index resources), and FDA medical reviews (reference standard). We estimated the magnitude of deviations in rates of SAEs and mortality between the index resources and the reference standard.

RESULTS: We found deviations in rates of SAEs (30% in ClinicalTrials.gov and 30% in corresponding journal articles) and mortality (72% in ClinicalTrials.gov and 53% in corresponding journal articles) when compared with the reference standard. The intra-class correlation coefficient between the three resources was 0.99 (95% confidence interval [CI] 0.98-0.99) for SAE rates and 0.99 (95% CI 0.97-0.99) for mortality rates.

CONCLUSION: There are differences in data on rates of SAEs and mortality in randomized clinical trials in both ClinicalTrials.gov and journal articles compared with FDA reviews. Further efforts should focus on decreasing existing discrepancies to enhance the transparency and reproducibility of data reporting in clinical trials.

References

  1. Contemp Clin Trials. 2017 Jun;57:87-89 - PubMed
  2. Ann Intern Med. 2016 Sep 20;165(6):421-30 - PubMed
  3. Ann Intern Med. 2014 Apr 1;160(7):477-83 - PubMed
  4. Res Synth Methods. 2018 Mar;9(1):2-12 - PubMed
  5. Trials. 2012 Aug 20;13:138 - PubMed
  6. Clin Investig (Lond). 2015;5(2):161-173 - PubMed
  7. J Clin Epidemiol. 2016 Sep;77:125-133 - PubMed
  8. BMJ. 2012 Jan 03;344:d7292 - PubMed
  9. PLoS Med. 2016 Sep 20;13(9):e1002127 - PubMed
  10. BMC Med. 2015 Aug 14;13:189 - PubMed
  11. BMJ Open. 2013 Jan 18;3(1):null - PubMed
  12. N Engl J Med. 2017 Jan 26;376(4):383-391 - PubMed
  13. BMJ. 2016 Feb 01;352:i157 - PubMed

MeSH terms

Publication Types